Press release, April 25, 2024
Quantum Genomics announces that it has obtained approval from the General Meeting of Shareholders on the reduction of its share capital and the contribution in kind of 100% of ExactCure shares.
The Quantum Genomics Company (Euronext Growth – FR0011648971 – ALQGC) announces that, as part of its merger project with Exactcure, a French HealthTech developing artificial intelligence software making it possible to adapt the taking of medications to the profile of each individual, the operations concerning the reduction of its share capital and the contribution of 100% of ExactCure securities were approved by the Shareholders at the General Meeting held on April 24, 2024